SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Poulvac Maternavac® IBD-Reo

Trade Name: POULVAC®, MATERNAVAC®
Synonyms: Bursal Disease-Reovirus Vaccine, Standard and Variant, Killed Virus
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Veterinary Vaccine
Restrictions on Use: Not for human use

Details of the Supplier of the Safety Data Sheet

Zoetis Inc.
100 Campus Drive, P.O. Box 651
Florham Park, New Jersey 07932 (USA)
Rocky Mountain Poison Control Center Phone: 1-866-531-8896
Product Support/Technical Services Phone: 1-800-366-5288

Zoetis Belgium S.A.
Mercuriusstraat 20
1930 Zaventem
Belgium

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: VMIPSrecords@zoetis.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Appearance: Pale Yellow to Reddish White liquid

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements

Signal Word: Not Classified

Hazard Statements: Non-hazardous in accordance with international standards for workplace safety.

Other Hazards

Short Term: In the event of accidental injection, an allergic reaction may occur. If an allergic reaction occurs, the worker should be removed to the nearest emergency room and the appropriate therapy instituted. This product is an oil-adjuvanted suspension. Oil-adjuvant containing products may cause severe vasospasm following accidental injection. May cause eye and skin irritation

Australian Hazard Classification (NOHSC): Non-Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Gentamicin	1403-66-3	215-765-8	Not Listed	Not Listed	##
Amphotericin B	1397-89-3	215-742-2	Not Listed	Not Listed	##
Formaldehyde	50-00-0	200-001-8	T; R23/24/25 C; R34 Carc.Cat.3; R40 R43	Acute Tox. 3 (H301) Skin Corr. 1B (H314) Skin Sens. 1 (H317) Carc. 2 (H351) Acute Tox. 3 (H331)	##

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Adjuvant - oil emulsion	Proprietary	Not Listed	Not Listed	Not Listed	*
Reovirus	Not assigned	Not Listed	Not Listed	Not Listed	*
Bursal Disease Virus	Not Assigned	Not Listed	Not Listed	Not Listed	*

Additional Information: ## Trace
* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: No data available

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: Where parenteral oil-adjuvanted vaccine exposure has occurred, the patient should be promptly evaluated for the development of vasospasm and/or compartment syndrome.

5. FIRE-FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of the spill or leak. Use non-combustible absorbent material to wipe up spill and place in a sealed container for disposal.

Additional Consideration for Large Spills: Contain the source of the spill or leak if it is safe to do so. Prevent discharge to drains. Dike, pump, or use non-combustible material to absorb spill; then place in a labeled container for disposal. Close container and move it to a secure holding area.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid accidental injection. Use with adequate ventilation. Avoid contact with eyes, skin and clothing. Avoid breathing vapor or mist. Use appropriate personal protective equipment. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Gentamicin

Bulgaria OEL - TWA	0.1 mg/m^3

Formaldehyde

ACGIH Ceiling Threshold Limit:	0.3 ppm
ACGIH - Sensitizer Designation	Sensitizer
Australia STEL	2 ppm 2.5 mg/m^3
Australia TWA	1 ppm 1.2 mg/m^3
Austria OEL - MAKs	0.5 ppm 0.6 mg/m^3
Bulgaria OEL - TWA	1.0 mg/m^3
Czech Republic OEL - TWA	0.5 mg/m^3
Estonia OEL - TWA	0.5 ppm 0.6 mg/m^3
Finland OEL - TWA	0.3 ppm 0.37 mg/m^3
France OEL - TWA	0.5 ppm
Germany (DFG) - MAK	0.3 ppm 0.37 mg/m^3 no irritation should occur during mixed exposure
Greece OEL - TWA	2 ppm 2.5 mg/m^3
Hungary OEL - TWA	0.6 mg/m^3
Ireland OEL - TWAs	2 ppm 2.5 mg/m^3
Japan - OELs - Ceilings	0.2 ppm 0.24 mg/m^3
Latvia OEL - TWA	0.5 mg/m^3
Lithuania OEL - TWA	0.5 ppm 0.6 mg/m^3
Netherlands OEL - TWA	0.15 mg/m^3
Vietnam O EL - TWAs	0.5 mg/m^3
OSHA - Final PELS - TWAs:	0.75 ppm
OSHA - Specifically Regulated Chemicals	2 ppm 0.5 ppm 0.75 ppm
Poland OEL - TWA	0.5 mg/m^3
Romania OEL - TWA	1 ppm 1.20 mg/m^3
Slovakia OEL - TWA	0.3 ppm 0.37 mg/m^3
Slovenia OEL - TWA	0.5 ppm 0.62 mg/m^3
Sweden OEL - TWAs	0.3 ppm 0.37 mg/m^3
Switzerland OEL -TWAs	0.3 ppm 0.37 mg/m^3

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Gentamicin

Zoetis OEB OEB 2 (control exposure to the range of 100ug/m^3 to < 1000ug/m^3)

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or aerosols. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Wear impervious gloves if skin contact is possible.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If airborne exposures are within or exceed the OEB, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEB range. Respiratory protection should be worn to supplement engineering controls when handling this compound.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Opaque liquid	**Color:**	Pale Yellow to Reddish White
Odor:	Odorless	**Odor Threshold:**	No data available.
Molecular Formula:	Mixture	**Molecular Weight:**	Mixture

Solvent Solubility: No data available
Water Solubility: Miscible:
pH: 6 - 8
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)
No data available
Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammablity:

Autoignition Temperature (Solid) (°C): No data available
Flammability (Solids): No data available
Flash Point (Liquid) (°C): Non-flammable
Upper Explosive Limits (Liquid) (% by Vol.): No data available
Lower Explosive Limits (Liquid) (% by Vol.): No data available
Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: High temperatures
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: Thermal decomposition products may include carbon monoxide, carbon dioxide and other toxic vapors.

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: Toxicological properties of the formulation have not been fully investigated. The following information is available for the individual ingredients. The antigens included in this product are non-infectious. All have been prepared from killed or inactivated preparations of microorganisms.

Acute Toxicity: (Species, Route, End Point, Dose)

Gentamicin
Rat Oral LD50 6600 mg/kg
Rat Subcutaneous LD50 710mg/kg
Mouse IM LD50 167 mg/kg
Rat IM LD50 463 mg/kg

Amphotericin B
Rat Oral LD50 > 5000 mg/kg
Rat Para-periosteal LD50 1.6mg/kg
Rat Intraperitoneal LD50 > 5000mg/kg
Mouse Intravenous LD50 1.2mg/kg
Mouse Intraperitoneal LD50 27.7mg/kg

Formaldehyde
Rat Oral LD50 800 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Gentamicin
Eye Irritation Rabbit Non-irritating

Formaldehyde
Eye Irritation Rabbit Severe
Skin Irritation Rabbit Moderate Severe

Amphotericin B
30 Day(s) Dog Intravenous 37 mg/kg/day LOAEL Kidney

11. TOXICOLOGICAL INFORMATION

2 Month(s) Dog Intravenous 16.5 mg/kg/day LOAEL Kidney
13 Week(s) Rat Oral 2 mg/kg/day NOAEL Male reproductive system, Female reproductive system
13 Week(s) Dog Oral 1.6 mg/kg/day NOAEL Male reproductive system, Female reproductive system

Formaldehyde
90 Day(s) Dog Inhalation Not Specified Lungs
90 Day(s) Rat Inhalation Not Specified Lungs
90 Day(s) Monkey Inhalation Not Specified Lungs
9 Day(s) Rat Inhalation 15 ppm LOAEL Respiratory system

Gentamicin
Embryo / Fetal Development Rat Intramuscular 75 mg/kg/day LOAEL Developmental toxicity

Amphotericin B
Embryo / Fetal Development Rat Oral 7.5 mg/kg/day NOAEL Not teratogenic, Fetotoxicity
Embryo / Fetal Development Rabbit Oral 10 mg/kg/day NOAEL Not Teratogenic, Fetotoxicity

Formaldehyde
Embryo / Fetal Development Mouse Oral 185 mg/kg/day Not teratogenic, Maternal toxicity
Embryo / Fetal Development Rat Inhalation 40 ppm Not Teratogenic, Maternal Toxicity

Amphotericin B
Bacterial Mutagenicity (Ames) *Salmonella* , *E. coli* Negative
In Vivo Micronucleus Mouse Negative
In Vitro Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative

Formaldehyde
In Vitro Bacterial Mutagenicity (Ames) Bacteria Positive
In Vitro Chromosome Aberration Rodent Positive
In Vitro Sister Chromatid Exchange Rodent Positive
In Vivo Chromosome Aberration Not specified Positive

Formaldehyde
2 Year(s) Rat Inhalation 6 ppm LOAEL Tumors
2 Year(s) Mouse Inhalation 15 ppm LOAEL Tumors

Carcinogen Status: None of the components present in this material at concentrations equal to or greater than 0.1% are listed by IARC, NTP, OSHA, or ACGIH as a carcinogen.

Formaldehyde
IARC: Group 1 (Carcinogenic to Humans)
NTP: Known Human Carcinogen
OSHA: Listed

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties of the formulation have not been investigated. The following information is available for the individual ingredients. Releases to the environment should be avoided.

Toxicity:

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Formaldehyde

RCRA - U Series Wastes Listed

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

15. REGULATORY INFORMATION

Gentamicin

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	215-765-8

Amphotericin B

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	215-742-2

Formaldehyde

CERCLA/SARA 313 Emission reporting	0.1 %
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	100 lb 45.4 kg
CERCLA/SARA - Section 302 Extremely Hazardous TPQs	500 lb
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	100 lb
California Proposition 65	carcinogen initial date 1/1/88 gas
OSHA - Specifically Regulated Chemicals	2 ppm 0.5 ppm 0.75 ppm
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 2 Schedule 6
EU EINECS/ELINCS List	200-001-8

Adjuvant - oil emulsion

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Reovirus

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Bursal Disease Virus

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed
Acute toxicity, inhalation-Cat.3; H331 - Toxic if inhaled
Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage
Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction
Carcinogenicity-Cat.2; H351 - Suspected of causing cancer

T - Toxic
C - Corrosive
Carcinogenic: Category 3

R34 - Causes burns.
R40 - Limited evidence of a carcinogenic effect
R43 - May cause sensitization by skin contact.
R23/24/25 - Toxic by inhalation, in contact with skin and if swallowed.

Data Sources: The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Prepared by: Toxicology and Hazard Communication
Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet